StockData
Bristol Myers Squibb Co logo

Bristol Myers Squibb Co (BMY) KPIs and segments

BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$59.56−1.79 (-2.92%)

Close on Nov 18, 2026Market cap $121.75BP/E 13.2Yield 4.18%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Bristol Myers Squibb · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026; Q3 2026 ended September 30, 2026)

Nhìn nhanh KPI của Bristol Myers Squibb: 55 chỉ số vận hành, trong đó có Total Revenues — Worldwide, Total Growth Portfolio — Worldwide net revenues và Total Legacy Portfolio — Worldwide net revenues, lấy từ 193 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Net product sales($M)
12,60612,58811,16812,11111,85011,90910,88611,81111,48311,92511,55911,168
Growth Portfolio($M)
7,6627,5606,2277,3936,8576,5965,5636,3635,8125,5964,7925,259
Legacy Portfolio($M)
5,4155,4225,2775,1095,3655,6735,6385,9796,0806,6057,0736,218
Eliquis($M)
4,6904,4814,1373,4523,7463,6803,5653,1953,0023,4163,7202,874
Opdivo($M)
2,3742,4852,1462,6932,5322,5602,2652,4792,3602,3872,0782,387
Orencia($M)
9831,0348181,0089649637701,000936948798985
Yervoy($M)
793769651810739728624675642630583566
Reblozyl($M)
750735555666615568478547447425354320
Other Growth products($M)
731653581210651557507527443348325326
Breyanzi($M)
526484411392359344263263224153107101
Alliance and other revenues($M)
463385321391372360315409276306
Camzyos($M)
4204163143542962601592231561398488
Other revenues($M)
368281227247241227304160172
Opdualag($M)
367349295350299284252254233235206190
Opdivo Qvantig($M)
334261163133673090000
Revlimid($M)
3034253496025758389361,3391,4121,3531,6691,450
Zeposia($M)
168169118159161150107158147151110133
Other Legacy products($M)
154170156199177223199250225222228231
Pomalyst/Imnovid($M)
130204513692675708658823898959865890
Abecma($M)
101137871031051249582100
Sotyktu($M)
1008769858070558366534463
Alliance revenues($M)
951049411512511988124105116134147
Sprycel($M)
73887380119120175198290424374526
Abraxane($M)
6555508474105105174253231217247
Krazati($M)
58555056534848393432210
Cobenfy($M)
5763565043352710000
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)6
U S($M)
9,0748,9917,7888,5588,3298,5197,8738,5968,2328,8018,4767,912
International($M)
3,5923,6643,4443,6353,6023,4813,1103,3963,3893,2243,1903,036
Other($M)
403318257309290270218350271176199184
Total Revenues — Worldwide ($M)($M)6
13,06912,97311,48912,50212,22212,26911,20112,34211,89212,20111,86511,477
Net Product Sales — Worldwide ($M)($M)1
12,60612,58811,16812,11111,85011,90910,88611,81111,48311,92511,55911,168
Net Product Sales — YoY growth (%)(%)
6.0%6.0%3.0%3.0%-6.0%8.0%9.0%5.0%
Alliance and Other Revenues — Worldwide ($M)($M)2
463385321391372360315531409276306309
Alliance Revenues ($M)($M)
951049411512511988124105116134147
Other Revenues (Royalties, Out-Licensing & Hedging) ($M)($M)1
368281227277247241227407304160172162
Revenue Hedging Activities ($M)($M)
-7-9-15000
Total Revenues — United States ($M)($M)1
9,0748,9917,7888,5588,3298,5197,8738,5968,2328,8018,4767,912
United States — GAAP revenue growth YoY (%)(%)
9.0%6.0%-1.0%1.0%-3.0%-7.0%9.0%9.0%13.0%7.0%1.0%
Total Revenues — International ($M)($M)4
3,9953,9823,7013,9443,8933,7503,3283,7463,6603,4003,3893,565
International — GAAP revenue growth YoY (%)(%)
3.0%6.0%11.0%5.0%6.0%10.0%-2.0%5.0%7.0%-1.0%
International — Excl. F/X revenue growth YoY (%)(%)
4.0%5.0%4.0%1.0%3.0%8.0%2.0%9.0%11.0%6.0%5.0%1.0%
International — F/X impact on YoY revenue growth (%)(%)
-1.0%1.0%7.0%5.0%3.0%3.0%-4.0%-4.0%-4.0%-7.0%-5.0%
Other Region (Unallocated Alliance & Royalty) Revenues ($M)($M)
403318257309290270218350271176199184
Worldwide — GAAP revenue growth YoY (%)(%)
7.0%6.0%3.0%1.0%3.0%1.0%-6.0%8.0%8.0%9.0%5.0%1.0%
Worldwide — Excl. F/X revenue growth YoY (%)(%)
7.0%5.0%1.0%2.0%-4.0%9.0%10.0%11.0%6.0%1.0%
Total Growth Portfolio — Worldwide net revenues ($M)($M)17
7,6627,5606,2277,3936,8576,5965,5636,3635,8125,5964,7925,259
Total Growth Portfolio — U.S. net revenues ($M)($M)1
4,9514,9743,8724,9584,4324,3483,6334,1723,8003,7853,0833,498
Total Growth Portfolio — U.S. GAAP revenue growth YoY (%)(%)
12.0%14.0%7.0%19.0%17.0%15.0%18.0%19.0%15.0%21.0%9.0%
Total Growth Portfolio — International net revenues ($M)($M)3
2,7112,5852,3552,4362,4252,2481,9302,1912,0121,8111,7091,761
Total Growth Portfolio — International GAAP revenue growth YoY (%)(%)
12.0%15.0%22.0%11.0%20.0%24.0%13.0%24.0%22.0%11.0%8.0%
Total Growth Portfolio — International Excl. F/X revenue growth YoY (%)(%)
13.0%13.0%15.0%7.0%17.0%23.0%18.0%31.0%29.0%21.0%15.0%
Total Growth Portfolio — International F/X impact on YoY growth (%)(%)
-1.0%2.0%7.0%5.0%3.0%2.0%-5.0%-7.0%-7.0%-10.0%-7.0%
Total Growth Portfolio — Worldwide GAAP revenue growth YoY (%)(%)
12.0%15.0%12.0%16.0%18.0%18.0%16.0%21.0%18.0%18.0%8.0%
Total Growth Portfolio — Worldwide Excl. F/X revenue growth YoY (%)(%)
12.0%14.0%9.0%15.0%17.0%17.0%18.0%23.0%20.0%21.0%11.0%
Opdivo (nivolumab — PD-1 Immuno-Oncology) — Worldwide net revenues ($M)($M)4
2,3742,4852,1462,6932,5322,5602,2652,4792,3602,3872,0782,387
Opdivo (nivolumab — PD-1 Immuno-Oncology) — U.S. net revenues ($M)($M)1
1,3451,4171,1591,6111,4541,5061,3321,4231,3661,4061,1551,401
Opdivo (nivolumab — PD-1 Immuno-Oncology) — U.S. GAAP revenue growth YoY (%)(%)
-8.0%-6.0%-13.0%13.0%6.0%7.0%15.0%2.0%2.0%15.0%-10.0%12.0%
Opdivo (nivolumab — PD-1 Immuno-Oncology) — International net revenues ($M)($M)2
1,0291,0689881,0821,0771,0539331,056994981923986
Opdivo (nivolumab — PD-1 Immuno-Oncology) — International GAAP revenue growth YoY (%)(%)
-4.0%1.0%6.0%2.0%8.0%7.0%1.0%7.0%7.0%6.0%3.0%
Opdivo (nivolumab — PD-1 Immuno-Oncology) — International Excl. F/X revenue growth YoY (%)(%)
-4.0%-1.0%-1.0%-2.0%6.0%7.0%7.0%15.0%16.0%18.0%9.0%4.0%
Opdivo (nivolumab — PD-1 Immuno-Oncology) — Worldwide GAAP revenue growth YoY (%)(%)
-6.0%-3.0%-5.0%9.0%7.0%7.0%9.0%4.0%4.0%11.0%-6.0%8.0%
Opdivo (nivolumab — PD-1 Immuno-Oncology) — Worldwide Excl. F/X revenue growth YoY (%)(%)
-6.0%-4.0%-8.0%7.0%6.0%7.0%12.0%7.0%7.0%16.0%-2.0%8.0%
Opdivo Qvantig (subcutaneous nivolumab + hyaluronidase-nvhy) — Worldwide net revenues ($M)($M)2
334261163133673090000
Opdivo Qvantig (subcutaneous nivolumab + hyaluronidase-nvhy) — U.S. net revenues ($M)($M)
25020613110860288
Opdivo Qvantig (subcutaneous nivolumab + hyaluronidase-nvhy) — International net revenues ($M)($M)
8455322571
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — Worldwide net revenues ($M)($M)4
9831,0348181,0089649637701,000936948798985
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — U.S. net revenues ($M)($M)1
754801590749721711555750706742572755
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — U.S. GAAP revenue growth YoY (%)(%)
5.0%13.0%6.0%2.0%-4.0%-3.0%-1.0%7.0%4.0%8.0%
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — International net revenues ($M)($M)3
230233228259243252215250230206226230
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — International GAAP revenue growth YoY (%)(%)
-6.0%-8.0%6.0%3.0%6.0%23.0%-5.0%9.0%6.0%-11.0%6.0%8.0%
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — International Excl. F/X revenue growth YoY (%)(%)
-4.0%-8.0%6.0%1.0%3.0%20.0%-1.0%15.0%13.0%-2.0%13.0%11.0%
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — International F/X impact on YoY growth (%)(%)
-1.0%1.0%6.0%4.0%2.0%3.0%-4.0%-6.0%-7.0%-9.0%-7.0%-3.0%
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — Worldwide GAAP revenue growth YoY (%)(%)
2.0%7.0%6.0%1.0%3.0%2.0%-4.0%2.0%1.0%2.0%4.0%8.0%
Orencia (abatacept — Immunology / Rheumatoid Arthritis) — Worldwide Excl. F/X revenue growth YoY (%)(%)
2.0%7.0%5.0%2.0%1.0%-2.0%3.0%3.0%5.0%6.0%9.0%
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — Worldwide net revenues ($M)($M)4
793769651810739728624675642630583566
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — U.S. net revenues ($M)($M)1
482481367525455451394428399404368340
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — U.S. GAAP revenue growth YoY (%)(%)
6.0%7.0%-7.0%23.0%14.0%12.0%7.0%26.0%11.0%10.0%18.0%-1.0%
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — International net revenues ($M)($M)3
311288284284284277230247243226215226
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — International GAAP revenue growth YoY (%)(%)
10.0%4.0%24.0%15.0%17.0%22.0%7.0%9.0%10.0%4.0%10.0%
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — International Excl. F/X revenue growth YoY (%)(%)
10.0%2.0%16.0%10.0%13.0%21.0%12.0%15.0%17.0%11.0%17.0%1.0%
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — International F/X impact on YoY growth (%)(%)
-1.0%2.0%8.0%6.0%4.0%2.0%-6.0%-6.0%-7.0%-7.0%-7.0%-1.0%
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — Worldwide GAAP revenue growth YoY (%)(%)
7.0%6.0%4.0%20.0%15.0%16.0%7.0%19.0%11.0%8.0%15.0%
Yervoy (ipilimumab — CTLA-4 Immuno-Oncology) — Worldwide Excl. F/X revenue growth YoY (%)(%)
8.0%5.0%2.0%18.0%14.0%15.0%9.0%22.0%13.0%10.0%18.0%
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — Worldwide net revenues ($M)($M)4
750735555666615568478547447425354320
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — U.S. net revenues ($M)($M)1
610593440552494453390445358348293270
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — U.S. GAAP revenue growth YoY (%)(%)
23.0%31.0%13.0%24.0%38.0%30.0%33.0%65.0%79.0%96.0%88.0%75.0%
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — International net revenues ($M)($M)3
1401421161141211148910289776150
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — International GAAP revenue growth YoY (%)(%)
16.0%24.0%30.0%12.0%35.0%51.0%44.0%104.0%85.0%38.0%22.0%10.0%
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — International Excl. F/X revenue growth YoY (%)(%)
18.0%24.0%23.0%6.0%31.0%46.0%49.0%110.0%90.0%41.0%22.0%5.0%
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — International F/X impact on YoY growth (%)(%)
-1.0%1.0%8.0%6.0%4.0%5.0%-5.0%-6.0%-5.0%-3.0%5.0%
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — Worldwide GAAP revenue growth YoY (%)(%)
22.0%29.0%16.0%22.0%37.0%34.0%35.0%71.0%80.0%82.0%72.0%61.0%
Reblozyl (luspatercept-aamt — Hematology Erythroid Maturation) — Worldwide Excl. F/X revenue growth YoY (%)(%)
22.0%29.0%15.0%21.0%37.0%33.0%36.0%72.0%81.0%82.0%72.0%60.0%
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — Worldwide net revenues ($M)($M)4
526484411392359344263263224153107101
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — U.S. net revenues ($M)($M)1
3593542922842512552042091731228785
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — U.S. GAAP revenue growth YoY (%)(%)
43.0%39.0%43.0%37.0%45.0%110.0%133.0%146.0%125.0%47.0%50.0%
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — International net revenues ($M)($M)2
16713112010710988605451312016
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — International GAAP revenue growth YoY (%)(%)
53.0%48.0%101.0%94.0%115.0%183.0%82.0%54.0%23.0%
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — International Excl. F/X revenue growth YoY (%)(%)
57.0%47.0%87.0%85.0%104.0%167.0%94.0%54.0%23.0%
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — Worldwide GAAP revenue growth YoY (%)(%)
46.0%41.0%56.0%49.0%60.0%125.0%146.0%160.0%143.0%53.0%51.0%84.0%
Breyanzi (lisocabtagene maraleucel — CD19 CAR-T) — Worldwide Excl. F/X revenue growth YoY (%)(%)
48.0%41.0%53.0%47.0%58.0%122.0%148.0%162.0%143.0%55.0%51.0%84.0%
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — Worldwide net revenues ($M)($M)4
367349295350299284252254233235206190
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — U.S. net revenues ($M)($M)1
305294246306259252228233216223198186
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — U.S. GAAP revenue growth YoY (%)(%)
18.0%17.0%8.0%31.0%20.0%13.0%15.0%25.0%33.0%48.0%71.0%80.0%
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — International net revenues ($M)($M)3
6255494440322521171284
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — International GAAP revenue growth YoY (%)(%)
57.0%72.0%98.0%109.0%122.0%161.0%
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — International Excl. F/X revenue growth YoY (%)(%)
56.0%65.0%81.0%98.0%115.0%155.0%
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — International F/X impact on YoY growth (%)(%)
1.0%6.0%17.0%11.0%7.0%7.0%
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — Worldwide GAAP revenue growth YoY (%)(%)
23.0%23.0%17.0%38.0%28.0%21.0%23.0%34.0%40.0%53.0%76.0%83.0%
Opdualag (nivolumab + relatlimab-rmbw — LAG-3/PD-1) — Worldwide Excl. F/X revenue growth YoY (%)(%)
23.0%22.0%15.0%37.0%27.0%20.0%23.0%34.0%40.0%53.0%76.0%83.0%
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — Worldwide net revenues ($M)($M)4
4204163143542962601592231561398488
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — U.S. net revenues ($M)($M)1
2993102292862382141262011351307783
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — U.S. GAAP revenue growth YoY (%)(%)
26.0%45.0%82.0%42.0%76.0%65.0%63.0%142.0%101.0%
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — International net revenues ($M)($M)3
12110585685746332221975
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — International GAAP revenue growth YoY (%)(%)
111.0%129.0%155.0%177.0%
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — International Excl. F/X revenue growth YoY (%)(%)
109.0%124.0%137.0%168.0%
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — International F/X impact on YoY growth (%)(%)
2.0%5.0%18.0%9.0%
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — Worldwide GAAP revenue growth YoY (%)(%)
42.0%60.0%97.0%59.0%89.0%87.0%89.0%153.0%129.0%
Camzyos (mavacamten — Cardiovascular Obstructive HCM) — Worldwide Excl. F/X revenue growth YoY (%)(%)
42.0%59.0%94.0%57.0%88.0%86.0%90.0%153.0%129.0%
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — Worldwide net revenues ($M)($M)5
168169118159161150107158147151110133
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — U.S. net revenues ($M)($M)1
115116691131131056111510511172100
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — U.S. GAAP revenue growth YoY (%)(%)
2.0%11.0%14.0%-2.0%8.0%-5.0%-16.0%15.0%11.0%52.0%41.0%74.0%
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — International net revenues ($M)($M)3
535349464846464342403833
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — International GAAP revenue growth YoY (%)(%)
11.0%17.0%7.0%9.0%13.0%15.0%22.0%30.0%50.0%48.0%41.0%52.0%
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — International Excl. F/X revenue growth YoY (%)(%)
13.0%14.0%-3.0%1.0%6.0%10.0%26.0%33.0%46.0%48.0%41.0%43.0%
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — International F/X impact on YoY growth (%)(%)
-2.0%2.0%10.0%9.0%6.0%5.0%-4.0%-3.0%4.0%9.0%
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — Worldwide GAAP revenue growth YoY (%)(%)
5.0%12.0%11.0%1.0%9.0%15.0%-3.0%19.0%20.0%51.0%41.0%68.0%
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — Worldwide Excl. F/X revenue growth YoY (%)(%)
5.0%12.0%7.0%-1.0%7.0%-2.0%-2.0%20.0%19.0%51.0%41.0%66.0%
Zeposia (ozanimod — S1P Modulator in MS & Ulcerative Colitis) — Worldwide F/X impact on YoY growth (%)(%)
-1.0%1.0%4.0%2.0%2.0%1.0%-1.0%-1.0%1.0%2.0%
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — Worldwide net revenues ($M)($M)4
1008769858070558366534463
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — U.S. net revenues ($M)($M)1
635135565143326451413456
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — U.S. GAAP revenue growth YoY (%)(%)
25.0%19.0%10.0%-13.0%5.0%-5.0%14.0%-18.0%71.0%
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — International net revenues ($M)($M)3
37363330292723191512107
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — International GAAP revenue growth YoY (%)(%)
27.0%30.0%43.0%71.0%91.0%116.0%138.0%171.0%
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — International Excl. F/X revenue growth YoY (%)(%)
26.0%27.0%34.0%65.0%87.0%109.0%146.0%171.0%71.0%
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — International F/X impact on YoY growth (%)(%)
1.0%2.0%9.0%6.0%4.0%7.0%-9.0%
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — Worldwide GAAP revenue growth YoY (%)(%)
26.0%23.0%24.0%4.0%21.0%31.0%27.0%32.0%
Sotyktu (deucravacitinib — TYK2 Inhibitor in Plaque Psoriasis) — Worldwide Excl. F/X revenue growth YoY (%)(%)
25.0%23.0%20.0%3.0%20.0%29.0%29.0%32.0%-18.0%
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — Worldwide net revenues ($M)($M)4
58555056534848393432210
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — U.S. net revenues ($M)($M)1
5447465248474436322921
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — U.S. GAAP revenue growth YoY (%)(%)
11.0%1.0%4.0%45.0%52.0%58.0%116.0%
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — International net revenues ($M)($M)
5833524323
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — Worldwide GAAP revenue growth YoY (%)(%)
10.0%14.0%4.0%41.0%58.0%51.0%125.0%
Krazati (adagrasib — KRAS G12C Inhibitor in NSCLC/CRC) — Worldwide Excl. F/X revenue growth YoY (%)(%)
10.0%14.0%3.0%41.0%57.0%51.0%125.0%
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — Worldwide net revenues ($M)($M)3
5763565043352710000
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — U.S. net revenues ($M)($M)1
5560565043352710
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — U.S. GAAP revenue growth YoY (%)(%)
29.0%73.0%107.0%
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — Worldwide GAAP revenue growth YoY (%)(%)
33.0%81.0%107.0%
Cobenfy (xanomeline and trospium chloride — Schizophrenia) — Worldwide Excl. F/X revenue growth YoY (%)(%)
33.0%81.0%107.0%
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — Worldwide net revenues ($M)($M)8
731653581210651557507527443348325326
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — U.S. net revenues ($M)($M)1
261244212212246248233199182175154165
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — U.S. GAAP revenue growth YoY (%)(%)
6.0%-1.0%-9.0%6.0%8.0%15.0%13.0%13.0%15.0%4.0%3.0%
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — International net revenues ($M)($M)2
470409369325405309274328261173171160
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — International GAAP revenue growth YoY (%)(%)
16.0%32.0%35.0%-1.0%22.0%56.0%34.0%104.0%61.0%30.0%26.0%
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — International Excl. F/X revenue growth YoY (%)(%)
17.0%32.0%32.0%-3.0%21.0%55.0%35.0%106.0%64.0%35.0%30.0%
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — Worldwide GAAP revenue growth YoY (%)(%)
12.0%17.0%15.0%2.0%16.0%35.0%24.0%58.0%39.0%16.0%14.0%
Other Growth Products (incl. Abecma, Augtyro, Empliciti, Inrebic, Nulojix, Onureg & Winrevair royalties) — Worldwide Excl. F/X revenue growth YoY (%)(%)
13.0%17.0%13.0%1.0%16.0%35.0%25.0%59.0%41.0%18.0%16.0%
Abecma (idecabtagene vicleucel — BCMA CAR-T) — Worldwide net revenues ($M)($M)5
101137871031051249582100
Abecma (idecabtagene vicleucel — BCMA CAR-T) — U.S. net revenues ($M)($M)1
525147595977545256
Abecma (idecabtagene vicleucel — BCMA CAR-T) — U.S. GAAP revenue growth YoY (%)(%)
-12.0%-34.0%-14.0%13.0%5.0%12.0%-53.0%-56.0%-40.0%
Abecma (idecabtagene vicleucel — BCMA CAR-T) — International net revenues ($M)($M)3
498640454647413044
Abecma (idecabtagene vicleucel — BCMA CAR-T) — International GAAP revenue growth YoY (%)(%)
7.0%80.0%-1.0%47.0%5.0%96.0%3.0%42.0%
Abecma (idecabtagene vicleucel — BCMA CAR-T) — International Excl. F/X revenue growth YoY (%)(%)
1.0%71.0%-7.0%54.0%5.0%100.0%7.0%39.0%
Abecma (idecabtagene vicleucel — BCMA CAR-T) — International F/X impact on YoY growth (%)(%)
6.0%9.0%5.0%-6.0%-4.0%-4.0%3.0%
Abecma (idecabtagene vicleucel — BCMA CAR-T) — Worldwide GAAP revenue growth YoY (%)(%)
-4.0%9.0%-8.0%26.0%5.0%33.0%-28.0%-44.0%-20.0%
Abecma (idecabtagene vicleucel — BCMA CAR-T) — Worldwide Excl. F/X revenue growth YoY (%)(%)
-6.0%6.0%-11.0%28.0%5.0%34.0%-27.0%-44.0%-21.0%
Abecma (idecabtagene vicleucel — BCMA CAR-T) — Worldwide F/X impact on YoY growth (%)(%)
3.0%4.0%2.0%-2.0%-1.0%-1.0%1.0%
Augtyro (repotrectinib — ROS1/NTRK TKI) — Worldwide net revenues ($M)($M)1
1510761
Augtyro (repotrectinib — ROS1/NTRK TKI) — U.S. net revenues ($M)($M)
1310761
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — Worldwide net revenues ($M)($M)4
29
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — U.S. net revenues ($M)($M)1
19
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — U.S. GAAP revenue growth YoY (%)(%)
12.0%
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — International net revenues ($M)($M)
10
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — Worldwide GAAP revenue growth YoY (%)(%)
26.0%
Inrebic (fedratinib — JAK2 Inhibitor in Myelofibrosis) — Worldwide Excl. F/X revenue growth YoY (%)(%)
26.0%
Onureg (oral azacitidine — AML Maintenance) — Worldwide net revenues ($M)($M)5
47
Onureg (oral azacitidine — AML Maintenance) — U.S. net revenues ($M)($M)1
31
Onureg (oral azacitidine — AML Maintenance) — U.S. GAAP revenue growth YoY (%)(%)
15.0%
Onureg (oral azacitidine — AML Maintenance) — International net revenues ($M)($M)2
16
Onureg (oral azacitidine — AML Maintenance) — International GAAP revenue growth YoY (%)(%)
60.0%
Onureg (oral azacitidine — AML Maintenance) — International Excl. F/X revenue growth YoY (%)(%)
50.0%
Onureg (oral azacitidine — AML Maintenance) — Worldwide GAAP revenue growth YoY (%)(%)
27.0%
Onureg (oral azacitidine — AML Maintenance) — Worldwide Excl. F/X revenue growth YoY (%)(%)
24.0%
Onureg (oral azacitidine — AML Maintenance) — Worldwide F/X impact on YoY growth (%)(%)
3.0%
Total Legacy Portfolio — Worldwide net revenues ($M)($M)10
5,4155,4225,2775,1095,3655,6735,6385,9796,0806,6057,0736,218
Total Legacy Portfolio — U.S. net revenues ($M)($M)1
4,1234,0173,9163,6003,8974,1714,2404,4244,4325,0165,3934,414
Total Legacy Portfolio — U.S. GAAP revenue growth YoY (%)(%)
6.0%-4.0%-8.0%-19.0%-12.0%-17.0%-21.0%4.0%7.0%5.0%
Total Legacy Portfolio — International net revenues ($M)($M)3
1,2921,4051,3611,5091,4681,5031,3981,5551,6481,5891,6801,804
Total Legacy Portfolio — International GAAP revenue growth YoY (%)(%)
-12.0%-7.0%-3.0%-3.0%-11.0%-6.0%-17.0%-14.0%-7.0%-11.0%-7.0%
Total Legacy Portfolio — International Excl. F/X revenue growth YoY (%)(%)
-10.0%-7.0%-10.0%-8.0%-14.0%-9.0%-14.0%-12.0%-6.0%-8.0%-4.0%
Total Legacy Portfolio — International F/X impact on YoY growth (%)(%)
-2.0%1.0%7.0%5.0%3.0%4.0%-3.0%-2.0%-1.0%-3.0%-3.0%
Total Legacy Portfolio — Worldwide GAAP revenue growth YoY (%)(%)
1.0%-4.0%-6.0%-15.0%-12.0%-14.0%-20.0%-4.0%1.0%2.0%2.0%
Total Legacy Portfolio — Worldwide Excl. F/X revenue growth YoY (%)(%)
1.0%-5.0%-8.0%-16.0%-13.0%-15.0%-20.0%-3.0%1.0%3.0%3.0%
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — Worldwide net revenues ($M)($M)4
4,6904,4814,1373,4523,7463,6803,5653,1953,0023,4163,7202,874
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — U.S. net revenues ($M)($M)1
3,6533,3573,0772,3082,6312,6542,6462,2212,0452,5442,8211,872
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — U.S. GAAP revenue growth YoY (%)(%)
39.0%27.0%16.0%4.0%29.0%4.0%-6.0%19.0%15.0%10.0%12.0%11.0%
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — International net revenues ($M)($M)3
1,0371,1241,0591,1441,1151,0279199749578728991,002
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — International GAAP revenue growth YoY (%)(%)
-7.0%9.0%15.0%18.0%16.0%18.0%2.0%-3.0%3.0%-2.0%1.0%
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — International Excl. F/X revenue growth YoY (%)(%)
-5.0%7.0%5.0%9.0%11.0%12.0%5.0%-2.0%2.0%7.0%1.0%-3.0%
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — International F/X impact on YoY growth (%)(%)
-2.0%2.0%10.0%8.0%6.0%6.0%-3.0%-1.0%1.0%-2.0%-1.0%4.0%
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — Worldwide GAAP revenue growth YoY (%)(%)
25.0%22.0%16.0%8.0%25.0%8.0%-4.0%11.0%11.0%7.0%9.0%7.0%
Eliquis (apixaban — Oral Factor Xa Anticoagulant) — Worldwide Excl. F/X revenue growth YoY (%)(%)
26.0%21.0%13.0%6.0%23.0%6.0%-3.0%11.0%11.0%7.0%9.0%6.0%
Revlimid (lenalidomide — Multiple Myeloma & MDS) — Worldwide net revenues ($M)($M)4
3034253496025758389361,3391,4121,3531,6691,450
Revlimid (lenalidomide — Multiple Myeloma & MDS) — U.S. net revenues ($M)($M)1
2393522785084857328091,1691,2121,1651,4531,244
Revlimid (lenalidomide — Multiple Myeloma & MDS) — U.S. GAAP revenue growth YoY (%)(%)
-51.0%-52.0%-66.0%-57.0%-60.0%-37.0%-44.0%-6.0%-4.0%-5.0%-38.0%
Revlimid (lenalidomide — Multiple Myeloma & MDS) — International net revenues ($M)($M)3
6372719489106127170200188216206
Revlimid (lenalidomide — Multiple Myeloma & MDS) — International GAAP revenue growth YoY (%)(%)
-29.0%-32.0%-44.0%-45.0%-55.0%-44.0%-41.0%-17.0%-9.0%-24.0%-5.0%-21.0%
Revlimid (lenalidomide — Multiple Myeloma & MDS) — International Excl. F/X revenue growth YoY (%)(%)
-28.0%-30.0%-45.0%-45.0%-56.0%-44.0%-39.0%-15.0%-6.0%-20.0%-1.0%-20.0%
Revlimid (lenalidomide — Multiple Myeloma & MDS) — International F/X impact on YoY growth (%)(%)
-1.0%-2.0%1.0%1.0%-3.0%-2.0%-3.0%-4.0%-4.0%-1.0%
Revlimid (lenalidomide — Multiple Myeloma & MDS) — Worldwide GAAP revenue growth YoY (%)(%)
-47.0%-49.0%-63.0%-55.0%-59.0%-38.0%-44.0%-8.0%-1.0%-8.0%-5.0%-36.0%
Revlimid (lenalidomide — Multiple Myeloma & MDS) — Worldwide Excl. F/X revenue growth YoY (%)(%)
-47.0%-49.0%-63.0%-55.0%-59.0%-38.0%-44.0%-7.0%-1.0%-7.0%-4.0%-36.0%
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — Worldwide net revenues ($M)($M)4
130204513692675708658823898959865890
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — U.S. net revenues ($M)($M)1
72131439624596584537685697716597627
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — U.S. GAAP revenue growth YoY (%)(%)
-88.0%-78.0%-18.0%-9.0%-15.0%-18.0%-10.0%9.0%15.0%27.0%10.0%1.0%
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — International net revenues ($M)($M)3
5873746779124122138201243268263
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — International GAAP revenue growth YoY (%)(%)
-27.0%-41.0%-39.0%-51.0%-61.0%-49.0%-55.0%-48.0%-24.0%-14.0%-8.0%2.0%
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — International Excl. F/X revenue growth YoY (%)(%)
-23.0%-38.0%-40.0%-51.0%-61.0%-51.0%-53.0%-47.0%-24.0%-11.0%-7.0%1.0%
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — International F/X impact on YoY growth (%)(%)
-4.0%-3.0%1.0%1.0%2.0%-1.0%-1.0%-3.0%-1.0%2.0%
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — Worldwide GAAP revenue growth YoY (%)(%)
-81.0%-71.0%-22.0%-16.0%-25.0%-26.0%-24.0%-8.0%3.0%13.0%4.0%1.0%
Pomalyst / Imnovid (pomalidomide — Multiple Myeloma) — Worldwide Excl. F/X revenue growth YoY (%)(%)
-80.0%-71.0%-22.0%-16.0%-25.0%-27.0%-24.0%-7.0%3.0%14.0%4.0%1.0%
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — Worldwide net revenues ($M)($M)4
73887380119120175198290424374526
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — U.S. net revenues ($M)($M)1
435236366968126135225341282411
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — U.S. GAAP revenue growth YoY (%)(%)
-38.0%-23.0%-71.0%-74.0%-69.0%-80.0%-56.0%-67.0%-44.0%6.0%-2.0%
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — International net revenues ($M)($M)3
3035374449524963658392115
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — International GAAP revenue growth YoY (%)(%)
-39.0%-32.0%-25.0%-30.0%-24.0%-38.0%-47.0%-45.0%-45.0%-39.0%-34.0%-32.0%
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — International Excl. F/X revenue growth YoY (%)(%)
-37.0%-30.0%-26.0%-31.0%-25.0%-38.0%-43.0%-41.0%-42.0%-34.0%-30.0%-31.0%
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — International F/X impact on YoY growth (%)(%)
-2.0%-2.0%1.0%1.0%1.0%-3.0%-4.0%-3.0%-5.0%-4.0%-1.0%
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — Worldwide GAAP revenue growth YoY (%)(%)
-38.0%-27.0%-58.0%-60.0%-59.0%-72.0%-53.0%-62.0%-44.0%-7.0%-13.0%-9.0%
Sprycel (dasatinib — Leukemia BCR-ABL Inhibitor) — Worldwide Excl. F/X revenue growth YoY (%)(%)
-38.0%-26.0%-59.0%-60.0%-59.0%-72.0%-53.0%-61.0%-43.0%-6.0%-11.0%-9.0%
Abraxane (nab-paclitaxel — Solid Tumors) — Worldwide net revenues ($M)($M)4
6555508474105105174253231217247
Abraxane (nab-paclitaxel — Solid Tumors) — U.S. net revenues ($M)($M)1
912122024334091151154145176
Abraxane (nab-paclitaxel — Solid Tumors) — U.S. GAAP revenue growth YoY (%)(%)
-61.0%-62.0%-71.0%-78.0%-84.0%-79.0%-72.0%-48.0%-15.0%-18.0%-10.0%53.0%
Abraxane (nab-paclitaxel — Solid Tumors) — International net revenues ($M)($M)2
5643386450726583102777271
Abraxane (nab-paclitaxel — Solid Tumors) — International GAAP revenue growth YoY (%)(%)
10.0%-40.0%-42.0%-24.0%-50.0%-7.0%-10.0%17.0%24.0%8.0%-8.0%11.0%
Abraxane (nab-paclitaxel — Solid Tumors) — International Excl. F/X revenue growth YoY (%)(%)
11.0%-40.0%-43.0%-23.0%-49.0%-5.0%-6.0%28.0%37.0%25.0%10.0%22.0%
Abraxane (nab-paclitaxel — Solid Tumors) — Worldwide GAAP revenue growth YoY (%)(%)
-13.0%-47.0%-53.0%-52.0%-71.0%-55.0%-52.0%-30.0%-3.0%-10.0%-9.0%38.0%
Abraxane (nab-paclitaxel — Solid Tumors) — Worldwide Excl. F/X revenue growth YoY (%)(%)
-12.0%-47.0%-54.0%-52.0%-70.0%-54.0%-50.0%-26.0%1.0%-6.0%-3.0%42.0%
Other Legacy Products (Mature Brands) — Worldwide net revenues ($M)($M)4
154170156199177223199250225222228231
Other Legacy Products (Mature Brands) — U.S. net revenues ($M)($M)1
106112741049210082123102969584
Other Legacy Products (Mature Brands) — U.S. GAAP revenue growth YoY (%)(%)
15.0%12.0%-10.0%-13.0%-11.0%5.0%-14.0%46.0%17.0%16.0%19.0%
Other Legacy Products (Mature Brands) — International net revenues ($M)($M)2
4958829685123116127123126133147
Other Legacy Products (Mature Brands) — International GAAP revenue growth YoY (%)(%)
-43.0%-53.0%-30.0%-27.0%-29.0%-4.0%-10.0%-14.0%-18.0%-24.0%-20.0%
Other Legacy Products (Mature Brands) — International Excl. F/X revenue growth YoY (%)(%)
-42.0%-53.0%-32.0%-28.0%-30.0%-5.0%-8.0%-15.0%-19.0%-19.0%-17.0%
Other Legacy Products (Mature Brands) — Worldwide GAAP revenue growth YoY (%)(%)
-13.0%-24.0%-21.0%-20.0%-21.0%-1.0%-12.0%8.0%-5.0%-10.0%-7.0%
Other Legacy Products (Mature Brands) — Worldwide Excl. F/X revenue growth YoY (%)(%)
-13.0%-24.0%-23.0%-21.0%-21.0%-1.0%-11.0%7.0%-5.0%-8.0%-6.0%
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — Worldwide net revenues ($M)($M)7
9,780
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — International net revenues ($M)1
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — International GAAP revenue growth YoY (%)(%)
1.0%
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — Worldwide GAAP revenue growth YoY (%)(%)
9.0%
Historical Classification (Pre-2024): Total In-Line & New Product Portfolio — Worldwide Excl. F/X revenue growth YoY (%)(%)
9.0%
Total In-Line Products (Pre-2024 Classification) — Worldwide net revenues ($M)($M)4
8,708
Total In-Line Products (Pre-2024 Classification) — U.S. net revenues ($M)($M)1
5,670
Total In-Line Products (Pre-2024 Classification) — U.S. GAAP revenue growth YoY (%)(%)
8.0%
Total In-Line Products (Pre-2024 Classification) — International net revenues ($M)($M)1
3,038
Total In-Line Products (Pre-2024 Classification) — International GAAP revenue growth YoY (%)(%)
-1.0%
Total In-Line Products (Pre-2024 Classification) — Worldwide GAAP revenue growth YoY (%)(%)
5.0%
Total In-Line Products (Pre-2024 Classification) — Worldwide Excl. F/X revenue growth YoY (%)(%)
5.0%
Total New Product Portfolio (Pre-2024 Classification) — Worldwide net revenues ($M)($M)5
1,072
Total New Product Portfolio (Pre-2024 Classification) — U.S. net revenues ($M)($M)1
894
Total New Product Portfolio (Pre-2024 Classification) — U.S. GAAP revenue growth YoY (%)(%)
71.0%
Total New Product Portfolio (Pre-2024 Classification) — International net revenues ($M)($M)2
178
Total New Product Portfolio (Pre-2024 Classification) — International GAAP revenue growth YoY (%)(%)
45.0%
Total New Product Portfolio (Pre-2024 Classification) — International Excl. F/X revenue growth YoY (%)(%)
39.0%
Total New Product Portfolio (Pre-2024 Classification) — Worldwide GAAP revenue growth YoY (%)(%)
66.0%
Total New Product Portfolio (Pre-2024 Classification) — Worldwide Excl. F/X revenue growth YoY (%)(%)
65.0%
Total New Product Portfolio (Pre-2024 Classification) — Worldwide F/X impact on YoY growth (%)(%)
1.0%
Mature and Other Products (Pre-2024 Classification) — Worldwide net revenues ($M)($M)3
480
Mature and Other Products (Pre-2024 Classification) — International net revenues ($M)1
Mature and Other Products (Pre-2024 Classification) — International GAAP revenue growth YoY (%)(%)
-6.0%
Mature and Other Products (Pre-2024 Classification) — Worldwide Excl. F/X revenue growth YoY (%)(%)
1.0%
Mature and Other Products (Pre-2024 Classification) — Worldwide F/X impact on YoY growth (%)(%)
-1.0%
Total Recent LOE Products (Pre-2024 Classification) — Worldwide net revenues ($M)($M)4
1,697
Total Recent LOE Products (Pre-2024 Classification) — U.S. net revenues ($M)($M)1
1,439
Total Recent LOE Products (Pre-2024 Classification) — U.S. GAAP revenue growth YoY (%)(%)
-33.0%
Total Recent LOE Products (Pre-2024 Classification) — International net revenues ($M)($M)1
258
Total Recent LOE Products (Pre-2024 Classification) — International Excl. F/X revenue growth YoY (%)(%)
-11.0%
Total Recent LOE Products (Pre-2024 Classification) — Worldwide GAAP revenue growth YoY (%)(%)
-30.0%
Total Recent LOE Products (Pre-2024 Classification) — Worldwide Excl. F/X revenue growth YoY (%)(%)
-30.0%
Gross Product Sales ($M)($M)2
17,96518,17916,92635,01522,49422,18119,87419,12321,22320,78019,29512,381
Gross Product Sales — YoY change (%)(%)
-20.0%-18.0%-15.0%6.0%7.0%3.0%14.0%15.0%12.0%
Total Gross-to-Net (GTN) Adjustments ($M)($M)6
-5,358-5,592-5,758-24,621-10,644-10,272-8,988-6,990-9,740-8,855-7,736-3,570
Charge-Backs and Cash Discounts ($M)($M)1
-2,268-2,372-2,467-6,959-3,475-3,407-2,958-1,670-2,967-2,843-2,556-778
Charge-Backs and Cash Discounts — YoY change (%)(%)
-35.0%-30.0%-17.0%17.0%20.0%16.0%25.0%25.0%22.0%
Medicaid and Medicare Rebates ($M)($M)1
-1,649-1,759-1,875-12,727-4,887-4,516-3,840-3,307-4,577-3,864-3,084-1,886
Medicaid and Medicare Rebates — YoY change (%)(%)
-66.0%-61.0%-51.0%7.0%17.0%25.0%23.0%23.0%24.0%
Other Rebates, Returns, Discounts and Adjustments ($M)($M)1
-1,441-1,460-1,416-4,936-2,281-2,348-2,190-2,013-2,196-2,148-2,096-906
Other Rebates, Returns, Discounts & Adjustments — YoY change (%)(%)
-37.0%-38.0%-35.0%4.0%9.0%4.0%16.0%21.0%26.0%
U.S. Gross-to-Net Adjustments (Disclosed in Note 2 Footnote) ($M)($M)
4,4004,7004,80010,5009,8009,5008,2009,7008,9008,0006,9007,700
Net Reduction/(Increase) to GTN Provisions from Prior-Period Sales ($M)($M)
12588-216787422895642-198018
Total GTN Adjustments — YoY change (%)(%)
-50.0%-46.0%-36.0%9.0%16.0%16.0%22.0%23.0%24.0%
Gross-to-Net (GTN) Adjustments Percentage — Total Company (%)(%)2
30.0%30.0%34.0%47.0%46.0%45.0%46.0%42.0%40.0%
U.S. GTN Adjustments Percentage (%)(%)
32.0%34.0%38.0%54.0%52.0%51.0%52.0%48.0%45.0%
Non-U.S. (International) GTN Adjustments Percentage (%)(%)
22.0%20.0%21.0%18.0%19.0%21.0%20.0%20.0%21.0%
Balance Sheet Accrued Rebates and Returns Liability (Current Liabilities) ($M)($M)1
4,9155,6545,3018,84411,2409,5398,4729,0219,6087,6866,9677,680
Cash Discounts & Charge-Backs Allowance Against Trade Receivables ($M)($M)
7828268571,720988949824900730686598646
Top 3 U.S. Wholesalers — Combined Share of Trade Accounts Receivable (%)(%)1
71.0%71.0%70.0%75.0%74.0%
Non-Recourse Factoring — Trade Accounts Receivable Sold ($M)($M)
213137931207275908375229231
Research and Development Expense — Total GAAP ($M)($M)5
2,3652,9592,6492,5862,5282,5802,2573,1912,3742,8992,6952,478
Drug Development Expense (Clinical Trials & Late-Stage Development) ($M)($M)
1,1401,1061,1271,2231,1511,0951,0811,2221,0941,0961,083
Research and Discovery Expense (Early-Stage Discovery & Preclinical) ($M)($M)
288274293423313291314479323336384
Other Research and Development Expense ($M)($M)
9371,5791,2299401,0631,1958611,4909571,4671,228
Acquired In-Process Research and Development (Acquired IPR&D) Line Item ($M)($M)
1,5580941,3936331,5081883026213212,949600
Accrued Research and Development Liability (Current Liabilities) ($M)($M)
1,7931,5621,5141,4341,3971,3841,3891,3661,3001,2311,2561,257
Collaborative Arrangements — Total Revenues Recognized ($M)($M)1
4,7954,5884,2423,5933,8803,8403,7233,3883,1963,5863,8963,076
Collaborative Arrangements — Net Product Sales ($M)($M)
4,7004,4854,1483,4783,7553,7203,6353,2643,0913,4703,7622,929
Royalty and Licensing Income (in Other Income/Expense, Net) ($M)($M)9
200186195396276162259204180191161420
Keytruda (pembrolizumab) — PD-1 Patent Royalty Income from Merck ($M)($M)
153149159154150132151139137137133308
Tecentriq (atezolizumab) — PD-L1 Patent Royalty Income from Roche ($M)($M)
131214131211121212111229
Other Out-Licensing & Royalty Income ($M)($M)
221310218102743566416
Out-Licensing Upfront & Contingent Milestone Income ($M)($M)
00000040361325055
Winrevair (sotatercept) — Royalty Revenue Received from Merck (in Other Growth Products) ($M)($M)
15113112478867842
Reblozyl (luspatercept) — Royalty Expense Paid to Merck (in COGS) ($M)($M)
169165124144132122106
Divestiture Royalty Income — Total ($M)($M)
000285286286272284284265271239
Accrued Royalties Payable (Current Liabilities) ($M)($M)
565552452537513495423477451422371465
Deferred Collaborations & Licensing Income (Noncurrent Liabilities) ($M)($M)1
128142155169180197213230247263282300
Amortization of Deferred Collaboration Income Recognized in Revenue ($M)($M)
121212121212121212121212
Non-GAAP Gross Margin (%)(%)1
0.1%0.1%0.1%1.0%0.1%0.1%
GAAP Gross Margin (%)(%)
68.3%71.3%70.2%71.9%72.5%72.9%
Non-GAAP Cost of Products Sold ($M)($M)2
4,1333,7113,4083,3123,3563,018
GAAP Cost of Products Sold ($M)($M)
4,1463,7263,4214,0973,4353,3723,0334,8122,9573,2672,9322,745
Specified Items in Cost of Products Sold ($M)($M)1
13151358912216141,6001012962238
Inventory Purchase Price Accounting Adjustments ($M)($M)
131313131313131313138
Non-GAAP Selling, General and Administrative (SG&A) Expense ($M)($M)1
1,6991,8261,6162,0871,7881,6911,5832,1051,9761,9221,9892,064
GAAP Selling, General and Administrative Expense ($M)($M)
1,6991,8261,6172,1811,7891,7131,5842,1361,9831,9282,3672,073
Non-GAAP Research and Development (R&D) Expense ($M)($M)2
2,3642,3162,2382,5612,4332,2632,2352,7882,3532,2952,3462,476
GAAP Research and Development Expense ($M)($M)
2,3652,9592,6492,5862,5282,5802,2573,1912,3742,8992,6952,478
Specified Items in R&D ($M)($M)1
1643411259531821403216043492
IPR&D Impairments in R&D ($M)($M)
42041085300390590
Amortization of Acquired Intangible Assets (100% Excluded from Non-GAAP) ($M)($M)
4584374378268318308301,6932,4062,4162,3572,278
Non-GAAP Other (Income)/Expense, Net ($M)($M)1
93126173-350-206-108-150-53-41-4-154-442
Specified Items in Other (Income)/Expense, Net ($M)($M)
214-187-1402999860248935827527723571
Non-GAAP Earnings Before Income Taxes ($M)($M)2
3,2234,9943,9613,3034,2623,5614,3264,2604,4864,885-8,175
GAAP Earnings/(Loss) Before Income Taxes ($M)($M)
2,5364,0863,2401,4703,1141,7732,9711751,6761,286-11,5161,674
Total Pre-Tax Specified Items (Increase to Pretax Earnings) ($M)($M)
6879087211,8331,1481,7881,3564,0852,8103,5993,341
Non-GAAP Income Tax Provision ($M)($M)2
456823723730950573652848832689732607
GAAP Income Tax Provision ($M)($M)
37477056138491946050999461-398392-88
Income Tax Effect on Specified Items ($M)($M)
8153161345311141437493711,087340695
Non-GAAP Effective Tax Rate (%)(%)1
-0.6%-2.4%0.9%-4.1%-7.2%-9.8%-2.1%-36.7%-9.0%45.0%-5.6%20.2%
GAAP Effective Tax Rate (%)(%)
14.8%18.8%17.3%26.2%29.5%25.9%17.1%56.6%27.5%-30.9%-3.4%-5.3%
Non-GAAP Net Earnings Attributable to BMS ($M)($M)2
2,7674,1723,2372,5743,3182,9853,6683,4083,6504,192-8,910
GAAP Net Earnings/(Loss) Attributable to BMS ($M)($M)
2,1623,3172,6771,0872,2011,3102,456721,2111,680-11,9111,762
Total After-Tax Specified Items (Increase to Net Earnings) ($M)($M)
6068555601,4871,1171,6741,2123,3362,4392,5123,001
Non-GAAP Diluted Earnings Per Share ($/sh)($)2
1.352.041.581.261.631.461.801.671.802.07-4.40
GAAP Diluted Earnings/(Loss) Per Share ($/sh)($)
1.051.621.310.531.080.641.200.040.600.83-5.89
Specified Items Per Diluted Share ($/sh)($)
0.300.420.270.730.550.820.591.631.201.241.49
GAAP Other (Income)/Expense, Net — Component Breakdown ($M)($M)11
307-6132-51-10849433930523427381-371
Interest Expense ($M)($M)
403407411432480485494496505521425316
Investment Income ($M)($M)
-118-101-104-148-161-139-138-114-94-87-183-145
Royalty and Licensing Income ($M)($M)
-200-186-195-396-276-162-259-204-180-191-161-420
Royalty Income — Divestitures ($M)($M)
-285-286-286-272-284-284-265-271-239
Provision for Restructuring ($M)($M)
18756513275223133777826022044
Litigation and Other Settlements ($M)($M)
3541016512571306923
Equity Investment (Gains)/Losses, Net ($M)($M)
26-114-134-190-1902278205-12-107-102-53
Acquisition Integration Expenses ($M)($M)
101719373632417069747162
Divestiture (Gains)/Losses, Net ($M)($M)
-13881
Contingent Consideration Fair Value Adjustments ($M)($M)
00150336000
Other Miscellaneous (Income)/Expense, Net ($M)($M)
-4-627-1840-19446105-23129
Total Restructuring & Exit Charges Across All P&L Lines ($M)($M)11
198-321225232279190199263357312128
Provision for Restructuring (in Other Income/Expense, Net) ($M)($M)
197-37-1169111255166147147334291106
Restructuring & Site Exit Costs in Cost of Products Sold ($M)($M)
020131103288831411
Restructuring & Site Exit Costs in Research and Development ($M)($M)
131710182113211412
Restructuring & Site Exit Costs in SG&A ($M)($M)
00037131317669
Employee Termination & Severance Benefits ($M)($M)
18048-212571220132697726021741
Accelerated Depreciation of Facilities ($M)($M)
1008912152022201414
Facility & Asset Impairment Charges ($M)($M)
01233111108893026
Contract Termination Costs ($M)($M)
687743181033
Site Shutdown & Other Exit Costs ($M)($M)
-241612-7241352
Strategic Productivity Initiative (2023 Restructuring Plan) — Period Charges ($M)($M)2
188-49-20180193231143911802646862
2023 Restructuring Plan — Cumulative Costs Incurred to Date ($M)($M)
1,9001,8001,8001,8001,6001,4001,2001,000
2023 Restructuring Plan — Total Expected Program Costs ($M)($M)
2,5002,5002,5002,5002,5002,5002,5002,5001,5001,5001,5001,000
Celgene Acquisition & Other Restructuring Plans — Period Charges ($M)($M)1
1017213948478393244
Celgene & Other Restructuring Plans — Remaining Expected Costs ($M)($M)
30456590115150200250
Restructuring Reserve Liability — Ending Balance ($M)($M)1
260150173315287353288297314431309188
Restructuring Cash Payments ( Utilization) ($M)($M)
7678143106142165145881981379783
Contingent Value Rights (CVR) Noncurrent Liability ($M)($M)
6076076076075925922562562482482480
Total Inventories (Current + Noncurrent) ($M)($M)5
4,2564,3694,3054,3404,4394,4124,3454,1264,4314,1063,9363,568
Current Inventories, Net ($M)($M)
2,7042,7372,7562,6902,7582,7372,6662,5573,3323,0772,9852,662
Noncurrent Inventories (Expected to Be Sold Beyond 12 Months) ($M)($M)
1,5521,6321,5491,6501,6811,6751,6791,5691,0991,029951906
Finished Goods ($M)($M)
9899938949001,0641,1571,2571,2571,080862885663
Work in Process (WIP) ($M)($M)
2,8943,0353,1013,1593,0632,9162,7682,5493,0082,8072,4962,430
Raw Materials and Supplies ($M)($M)
373341310281312339320320343437555475
Property, Plant and Equipment (PP&E), Net ($M)($M)3
7,9717,7917,6587,5437,3497,3737,2137,1366,9036,8456,7506,646
Property, Plant and Equipment, Gross ($M)($M)4
13,66013,34013,09012,83612,54412,68212,32412,08511,73911,93211,69311,449
Buildings and Improvements, Gross ($M)($M)
7,9727,9337,4867,2707,1246,8556,6406,5816,4706,6706,5466,495
Machinery, Equipment and Fixtures, Gross ($M)($M)
4,0413,9553,9063,7903,8073,9053,8673,8183,7413,8453,7723,717
Construction in Progress (CIP), Gross ($M)($M)
1,4831,2961,5411,6191,4561,7611,6561,5251,3671,2551,2131,075
Land, Gross ($M)($M)
164157157157157161161161161162162162
Accumulated Depreciation ($M)($M)
5,6885,5495,4315,2935,1955,3095,1114,9494,8365,0874,9434,803
Depreciation Expense ($M)($M)
151139139132159165165169166161155163
Goodwill ($M)($M)
21,73521,74021,74021,75421,74521,77621,73721,71921,75121,73221,73821,169
Other Intangible Assets, Net ($M)($M)8
16,93617,38718,24419,10320,46521,37822,48623,30726,96429,42832,76027,072
Other Intangible Assets, Gross ($M)($M)
71,65171,61272,03172,41873,09773,14673,38373,34075,31975,36076,36168,283
Finite-Lived Intangible Assets — Accumulated Amortization ($M)($M)
54,71554,22653,78653,31552,63251,76850,89750,03348,35545,93243,60141,211
Marketed Products (Acquired Drug Rights & Patents), Net ($M)($M)2
10,9549,0309,3849,73911,03611,77312,49013,21716,38718,74721,35722,892
Marketed Products, Gross ($M)($M)
63,65361,35361,38561,38561,93961,92761,89661,87663,43563,47363,87163,076
Marketed Products, Accumulated Amortization ($M)($M)
52,69952,32352,00051,64650,90350,15449,40648,65947,04844,72642,51440,184
Core & Developed Technology, Net ($M)($M)2
1,1281,2101,2931,3751,4571,5401,62213,2171,7871,8701,95222,892
Core & Developed Technology, Gross ($M)($M)
1,9801,9801,9801,9801,9801,9801,98061,8761,9801,98063,076
Core & Developed Technology, Accumulated Amortization ($M)($M)
85377068860552344035848,6591931102840,184
Capitalized Software, Net ($M)($M)2
384376377389372380389400415436486470
Capitalized Software, Gross ($M)($M)
1,5481,5091,4761,4531,5781,5541,5221,4991,5291,5321,5451,497
Capitalized Software, Accumulated Amortization ($M)($M)
1,1641,1331,0991,0641,2061,1741,1331,0991,1141,0961,0591,027
In-Process Research and Development (Indefinite-Lived IPR&D Assets) ($M)($M)
4,4706,7707,1907,6007,6007,6857,9857,9858,3758,3758,9653,710
Total Intangible Asset Amortization Expense ($M)($M)
4914714729008678648631,7002,4002,4002,4002,300
Intangible Asset Impairment Charges ($M)($M)
1,9834727
Receivables, Net ($M)($M)2
10,63910,5539,36811,41411,42211,41510,80110,74711,02611,42310,44710,921
Trade Accounts Receivable, Gross ($M)($M)
10,0359,9628,86011,37010,66410,7149,9329,95710,09210,4719,4489,551
Allowance for Expected Credit Losses ($M)($M)
605956585254454545392423
Net Debt Position (Cash & Marketable Debt Securities Less Total Debt) ($M)($M)3
-29,918-31,656-33,607-34,043-32,069-35,235-37,584-38,470-41,334-45,379-45,640-27,128
Cash, Cash Equivalents and Marketable Debt Securities ($M)($M)3
12,95911,46410,85311,06916,90913,95012,12611,1798,4187,01010,03712,644
Cash and Cash Equivalents ($M)($M)
9,5748,7229,57410,20915,72612,59910,87510,3467,8906,2939,33011,464
Marketable Debt Securities — Current ($M)($M)
3,0072,3459124647761,004907513204360340816
Marketable Debt Securities — Non-Current ($M)($M)
378397366396406346344320324357367364
Short-Term Debt Obligations ($M)($M)3
1,0281,0272,3082,2614,5094,7153,5542,0461,0783,5316,1903,119
Current Portion of Long-Term Debt ($M)($M)
7687681,9881,9774,2484,4753,3491,8288733,0922,8732,873
Short-Term Borrowings & Commercial Paper ($M)($M)
1,0281,0272,3082,2614,5094,7153,5542,0461,0783,5316,1903,119
Other Short-Term Loans ($M)($M)
260259319284261240205218205173164170
Long-Term Debt (Non-Current) ($M)($M)2
41,84942,09342,15242,85044,46944,47046,15747,60348,67448,85849,48736,653
Total Long-Term Debt incl. Current Portion (Carrying Value) ($M)($M)
42,61742,86144,14044,82748,71748,94549,50649,43149,54751,95052,36039,526
Total Long-Term Debt (Estimated Fair Value) ($M)($M)
36,00039,20040,20041,50045,80045,50046,00045,30047,90047,70049,20036,700
Operating Lease Right-of-Use (ROU) Assets ($M)($M)1
1,4801,4861,5281,5821,6041,2761,2151,2241,3481,3161,4361,390
Total Operating Lease Liabilities ($M)2
Operating Lease Liabilities — Current ($M)($M)
220207199202214194172181165177169162
Operating Lease Liabilities — Noncurrent ($M)($M)
1,7131,7261,7701,8261,8491,5501,3561,3701,4831,4381,5631,530
Cash Dividends Paid to Common Shareholders ($M)($M)4
1,2871,2871,2831,2621,2631,2621,2581,2181,2161,2171,2121,160
Dividends Declared per Common Share ($/sh)($)
0.630.630.630.620.620.620.600.600.60
Common Stock Repurchases — Cash Outflow ($M)($M)
00000
Treasury Stock — Carrying Value ($M)($M)
43,47143,50443,51543,57943,58643,59043,59743,65543,766
Stock-Based Compensation Expense — Total ($M)($M)4
138135146133139138144120129125133127
Stock-Based Compensation in Research and Development ($M)($M)
656472646666725762636661
Stock-Based Compensation in SG&A ($M)($M)
585658545856564853485353
Stock-Based Compensation in Cost of Products Sold ($M)($M)
161516151616151514141413
Income Tax Benefit Recognized for Stock-Based Compensation ($M)($M)
302830272929302627272825
Defined Benefit Pension Plans — Projected Benefit Obligation (PBO) ($M)2
Balance Sheet Noncurrent Pension Assets ($M)($M)
335332330330281270248234225210290284
Balance Sheet Noncurrent Pension & Postretirement Liability ($M)($M)
299307317330393415408400447466477480
Earnings/(Loss) Before Income Taxes — Geographic Split ($M)1
Deferred Income Tax Provision/(Benefit) — Total ($M)($M)
-510-195161-392-359-437223-791-256-331-711-1,327
Deferred Tax Assets, Gross (Before Valuation Allowance) ($M)2
Balance Sheet Deferred Income Tax Assets (Noncurrent) ($M)($M)
5,8845,3625,1765,3784,9614,6473,9974,2363,6093,3232,7232,768
Balance Sheet Deferred Income Tax Liabilities (Noncurrent) ($M)($M)
228222211222225247276369430461442338
Unrecognized Tax Benefits (UTB) — Ending Balance ($M)2
Income Taxes Payable — Current Liabilities ($M)($M)
7278069099791,0229181,4541,5141,4891,4741,4871,371
Income Taxes Payable — Noncurrent Liabilities (Transition Tax & UTB) ($M)($M)
9008301,3111,4071,7391,4381,5511,4911,5431,7833,3603,288
U.S. Personal Consumption Expenditures — Pharmaceutical & Other Medical Products (DHLCRC1Q027SBEA, $B SAAR)
3,858.703,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.40
Consolidated Statements of Earnings — Total Revenues ($M)($M)16
13,06912,97311,48912,50212,22212,26911,20112,34211,89212,20111,86511,477
Cost of Products Sold ($M)($M)
4,1463,7263,4214,0973,4353,3723,0334,8122,9573,2672,9322,745
Research and Development Expense ($M)($M)
2,3652,9592,6492,5862,5282,5802,2573,1912,3742,8992,6952,478
Selling, General and Administrative Expense ($M)($M)
1,6991,8261,6172,1811,7891,7131,5842,1361,9831,9282,3672,073
Restructuring Charges ($M)($M)
18756513175223133777826022044
Litigation and Settlement Charges ($M)($M)
-3-5-4-10-165-1-257-130-69-2-3
Total Expenses ($M)($M)
10,5338,8878,25011,0329,10810,4968,23012,16710,21610,91523,3819,803
Interest Expense ($M)($M)
403407411432480485494496505521425316
Investment / Interest Income ($M)($M)
1181011041481611391381149487183145
Earnings/(Loss) Before Income Taxes ($M)($M)
2,5364,0863,2401,4703,1141,7732,9711751,6761,286-11,5161,674
Income Tax Provision/(Benefit) ($M)($M)
37477056138491946050999461-398392-88
Net Earnings/(Loss) — Consolidated ($M)($M)
2,1623,3162,6781,0852,1951,3132,462761,2151,684-11,9081,762
Net Earnings/(Loss) Attributable to BMS ($M)($M)
2,1623,3172,6771,0872,2011,3102,456721,2111,680-11,9111,762
Basic Earnings/(Loss) Per Share ($/sh)($)
1.061.621.311.080.641.210.600.83-5.89
Diluted Earnings/(Loss) Per Share ($/sh)($)
1.051.621.311.080.641.200.600.83-5.89
Weighted-Average Basic Shares Outstanding (M shares)
2,0432,0422,0382,0362,0352,0312,0282,0272,023
Weighted-Average Diluted Shares Outstanding (M shares)
2,0532,0482,0472,0392,0382,0402,0312,0292,023
Consolidated Balance Sheets — Total Assets ($M)($M)9
88,77287,63486,47690,03896,88994,67692,42792,60393,67094,64699,03195,159
Total Current Assets ($M)($M)5
29,76728,57927,20829,39035,63033,22230,78329,78028,07526,89028,66931,770
Cash and Cash Equivalents ($M)($M)
9,5748,7229,57410,20915,72612,61110,87510,3477,8936,2969,33411,519
Marketable Debt Securities — Current ($M)($M)
3,0072,3459124647761,004907513204360340816
Receivables, Net ($M)($M)
9,1929,0777,9469,5929,6249,7119,0639,0129,3179,7468,8268,882
Inventories, Current ($M)($M)
2,7042,7372,7562,6902,7582,7372,6662,5573,3323,0772,9852,662
Other Current Assets ($M)($M)
3,8444,2224,5974,6134,9485,4665,5345,6175,6235,7375,5675,907
Property, Plant and Equipment, Net ($M)($M)
7,9717,7917,6587,5437,3497,3737,2137,1366,9036,8456,7506,646
Goodwill ($M)($M)
21,73521,74021,74021,75421,74521,77621,73721,71921,75121,73221,73821,169
Other Intangible Assets, Net ($M)($M)
16,93617,38718,24419,10320,46521,37822,48623,30726,96429,42832,76027,072
Marketable Debt Securities — Non-Current ($M)($M)
378397366396406346344320324357367364
Deferred Income Tax Assets ($M)($M)
5,8845,3625,1765,3784,9614,6473,9974,2363,6093,3232,7232,768
Other Non-Current Assets ($M)($M)
6,0996,3786,0826,4746,3325,9365,8666,1056,0446,0716,0245,370
Total Liabilities ($M)($M)3
65,36865,31566,37471,53378,28977,18774,97976,21576,47077,57782,48365,674
Total Current Liabilities ($M)($M)3
18,75318,65919,15823,41728,13627,52824,07023,77422,63823,26525,82222,262
Short-Term Debt Obligations ($M)($M)
1,0281,0272,3082,2614,5094,7153,5542,0461,0783,5316,1903,119
Accounts Payable ($M)($M)
4,6284,1584,2343,5754,2885,4274,0023,6023,4693,7513,5393,259
Other Current Liabilities (incl. Accrued Rebates & Royalties) ($M)($M)
13,09813,47412,61617,58119,33917,38616,51418,12618,09115,98316,09315,884
Long-Term Debt ($M)($M)
41,84942,09342,15242,85044,46944,47046,15747,60348,67448,85849,48736,653
Other Non-Current Liabilities ($M)($M)
4,5384,3414,8535,0435,4594,9424,4774,4694,7284,9936,7326,421
Total Stockholders' Equity ($M)($M)4
23,40422,31920,10218,50618,60017,48917,44816,38817,20017,06916,54829,485
Capital in Excess of Par Value of Stock ($M)($M)
46,67446,50446,37446,38746,26546,13446,01146,02445,89645,76645,65545,684
Retained Earnings ($M)($M)
21,19020,31618,28716,89617,09316,15416,10614,91216,09716,10315,64028,766
Less: Cost of Treasury Stock ($M)($M)
-43,471-43,504-43,515-43,579-43,586-43,590-43,597-43,655-43,675-43,690-43,697-43,766
Accumulated Other Comprehensive Loss ($M)($M)
-1,281-1,290-1,370-1,524-1,513-1,554-1,424-1,238-1,468-1,456-1,400-1,546
Consolidated Statements of Cash Flows — Operating Cash Flow ($M)($M)11
4,1813,3931,1041,9746,3113,9171,9544,4395,5912,3262,8344,252
Depreciation and Amortization ($M)($M)
6265945949771,0111,0111,0121,8802,5922,5962,5322,464
Stock-Based Compensation ($M)($M)
138135146133139138144120129125133127
Deferred Income Taxes ($M)($M)
-510-195161-392-359-437223-791-256-331-711-1,327
Change in Receivables ($M)($M)
-95-1,1831,68719155-48415143661-1,019479-508
Change in Inventories ($M)($M)
133-361471-904-169175-218-225-218-197
Change in Accounts Payable ($M)($M)
252-29409-9016013-85517-374-259300444
Capital Expenditures (Additions to PP&E and Capitalized Software) ($M)($M)
-344-305-347-370-320-361-260-378-324-262-284-330
Net Cash Provided by/(Used in) Investing Activities ($M)($M)
-2,104-1,614-131-1,458-1,702-473-499-196-219-1,319-19,618-1,346
Net Cash Provided by/(Used in) Financing Activities ($M)($M)
-1,222-2,630-1,560-6,029-1,490-1,836-993-1,642-3,852-4,02314,644967
Dividends Paid ($M)($M)
-1,287-1,287-1,283-1,262-1,263-1,262-1,258-1,218-1,216-1,217-1,212-1,160
Cash Paid for Interest ($M)($M)
511316473400700376624400665427308268

50 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Bristol-Myers Squibb Company (NYSE: BMY, CIK 0000014272) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026). BMS operates as a single global Biopharmaceuticals operating segment (Note 1), so commercial performance is tracked through Growth Portfolio vs. Legacy Portfolio and brand-level Worldwide / U.S. / International net revenues.
  • Core commercial & R&D KPIs (Groups 1–6) cover: (1) Consolidated Revenues ($13,069M in Q3 2026 / $48,194M in FY25 across Net Product Sales $12,606M and Alliance & Other Revenues $463M in Q3 2026; U.S. $9,074M and International $3,995M in Q3 2026; +7% GAAP / +7% Excl. F/X YoY); (2) Growth Portfolio ($7,662M in Q3 2026 / $26,419M in FY25, +12% GAAP / +12% Excl. F/X YoY in Q3 2026: Opdivo $2,374M, Orencia $983M, Yervoy $793M, Reblozyl $750M, Breyanzi $526M, Camzyos $420M, Opdualag $367M, Opdivo Qvantig $334M, Zeposia $168M, Sotyktu $100M, Krazati $58M, Cobenfy $57M, and Other Growth Products $731M, plus historical standalone series for Abecma, Augtyro, Inrebic, Onureg & Empliciti); (3) Legacy Portfolio ($5,415M in Q3 2026 / $21,775M in FY25: Eliquis $4,690M, Revlimid $303M, Pomalyst/Imnovid $130M, Sprycel $73M, Abraxane $65M, Other Legacy Products $154M) and pre-2024 In-Line / New Product / Recent LOE classifications; (4) Gross-to-Net (GTN) reconciliation ($17,965M Gross Product Sales less $5,358M Total GTN Adjustments = $12,606M Net Product Sales in Q3 2026; $88,085M Gross less $41,329M GTN = $46,756M Net in FY25; GTN % dropping from 47% Total / 53% U.S. in FY25 to 30% Total / 32% U.S. in Q3 2026 following the U.S. Eliquis list price cut), 12-year GTN reserve rollforwards ($10,565M ending reserve at FY25), and top-3 U.S. wholesaler concentration (McKesson 31%, Cencora 29%, Cardinal Health 15% of FY25 gross revenues; 83% of Q3 2026 trade AR); (5) R&D by stage ($2,365M GAAP R&D in Q3 2026: Drug Development $1,587M, Research & Discovery $511M, Other R&D $267M), strategic alliances (Pfizer Eliquis $6,980M COGS profit share in FY25; Ono Opdivo; Janssen Milvexian), and patent royalties (Keytruda $166M, Winrevair $151M, Tecentriq $12M received; Reblozyl $169M paid in Q3 2026); and (6) GAAP to Non-GAAP reconciliations (68.4% Non-GAAP Gross Margin, 14.1% Non-GAAP Effective Tax Rate, $1.35 Non-GAAP Diluted EPS in Q3 2026; $6.15 Non-GAAP Diluted EPS in FY25), Specified Items, and Other (Income)/Expense, net components.
  • Groups 7–12 cover: (7) Restructuring programs (2023 Strategic Productivity Initiative & Celgene Integration Plan across P&L lines and cost categories; $365M restructuring reserve at Q3 2026) and CVR liabilities; (8) Inventories by stage ($4,524M total inventories at Q3 2026: Current $2,824M, Noncurrent $1,700M; Finished Goods $1,089M, WIP $2,642M, Raw Materials $793M), PP&E by category ($6,456M net at Q3 2026), and Goodwill ($21,546M) & Intangible Assets ($26,876M net at Q3 2026 with 5-year estimated amortization schedule); (9) Net Debt Calculation ($29,918M net debt at Q3 2026: $12,959M cash & marketable debt securities vs. $1,028M short-term debt and $41,849M long-term debt), Operating Leases ($1,558M ROU assets at Q3 2026), Dividends ($0.63/sh declared in Q3 2026), Share Repurchases & Stock-Based Compensation; (10) Defined Benefit Pension ($2,424M PBO / $2,833M plan assets / +$409M funded status at FY25) & OPEB plans and Income Taxes (DTA/DTL & UTB rollforward $1,848M at FY25); (11) Global Workforce (32,500 employees across 43 countries, 54% U.S. in FY25), CEO Pay Ratio (131:1 / $167,191 median employee in FY25), Form 11-K Savings Plans ($12.75B net assets in U.S. SIPS, $203.9M in Puerto Rico Plan, $93.9M in Thrift Plan at FY25), and ESG / Sustainability (Scopes 1, 2 & 3 GHG emissions, energy, 44% renewable electricity share in FY24, water, waste & 0.30 injury rate in FY25); and (12) FRED pharmaceutical industry benchmarks and Consolidated Financial Statements from DB.
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as '>200%' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Dữ liệu cập nhật 2026-11-03.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

1. Consolidated Revenue Composition & Geographic Breakdown (Worldwide / U.S. / International)

2. Growth Portfolio — Brand Net Revenues & YoY Growth by Geography (WW / U.S. / Int'l)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Bristol Myers Squibb

See a number that looks wrong?